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Abstract
Background: Epidemic outbreaks of multi-drug resistant (MDR) Acinetobacter baumannii (AB) in intensive care units
(ICUs) are increasing. The incidence of MDR AB bacteremia, which develops as a result of colonization, is increasing
through widespread dissemination of the pathogen, and further colonization. We sought to determine risk factors
for MDR AB bacteremia in patients colonized with MDR AB in the ICU.
Methods: We conducted a retrospective, observational study of 200 patients colonized with MDR AB in the ICU at
Severance Hospital, South Korea during the outbreak period between January 2008 and December 2009.
Results: Of the 200 patients colonized with MDR AB, 108 developed MDR AB bacteremia, and 92 did not. APACHE
II scores were higher in bacteremic than non-bacteremic patients at the time of ICU admission and colonization
(24.0 vs. 21.6; P = 0.035, 22.9 vs. 16.8; P < 0.001, respectively). There was no difference between the two groups in
the duration of time from ICU admission to colonization (7.1 vs. 7.2 days; P = 0.923), but the duration of time at
risk was shorter in bacteremic patients (12.1 vs. 6.0 days; P = 0.016). A recent invasive procedure was a significant
risk factor for development of bacteremia (odds ratio = 3.85; 95% CI 1.45-10.24; P = 0.007). Multivariate analysis
indicated infection and respiratory failure at the time of ICU admission, maintenance of mechanical ventilation,
maintenance of endotracheal tube instead of switching to a tracheostomy, recent central venous catheter
insertion, bacteremia caused by other microorganism after colonization by MDR AB, and prior antimicrobial
therapy, were significant risk factors for MDR AB bacteremia.
Conclusions: Patients in the ICU, colonized with MDR AB, should be considered for minimizing invasive
procedures and early removal of the invasive devices to prevent development of MDR AB bacteremia.
Background
Acinetobacter baumannii (AB) is emerging as an impor-
tant pathogen, especially in intensive care units (ICUs).
The increasing development of multiple antimicrobial
resistances in this pathogen has severely restricted the
therapeutic options available for infected patients, and
increased the length of stay in ICUs and mortality [1,2].
Despite intensive efforts, nosocomial acquisition of
multi-drug resistant (MDR) AB is still a problem due to
the great ability of AB to disseminate from and colonize
human and environmental reservoirs [3,4].
Various studies using different methodologies have
analyzed risk factors associated with the acquisition of
AB. Most of them have addressed factors that influence
the risk of infection with MDR AB, comparing to infec-
tion with non-MDR AB, or non-AB [3-9]. These factors
include prior colonization, which was independently
related to the development of MDR AB bacteremia
[3,9], and colonization [3]. However, there is limited
data on risk factors associated with the development of
MDR AB bacteremia from colonization in ICUs.
Recently, major endemic and epidemic outbreaks of
MDR AB have developed in critically ill patients
throughout the world; aggressive control measures to
prevent the transmission and colonization of this
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pathogen are currently limited. The incidence of MDR
AB bacteremia has increased [10,11]; thus, efforts to
identify factors that influence the survival of patients
with this pathology have been made [2,12,13]. It is
known that mortality increases with each hour that
appropriate antimicrobial therapy is delayed in patients
with septic shock [14]. In several studies, inappropriate,
empirical, antimicrobial therapy was independently asso-
ciated with poor clinical outcome, and early, appropri-
ate, antimicrobial therapy was shown to improve
survival in patients with an MDR AB bloodstream infec-
tion [2,12,13].
We conducted a retrospective, observational study
among patients colonized with MDR AB admitted to
our ICU to assess risk factors associated with the devel-
opment of MDR AB nosocomial bacteremia. Knowledge
of these risk factors will allow recommendations for pre-
ventive and therapeutic guidelines for the patients colo-
nized with MDR AB.
Methods
Study subjects
This was a retrospective, observational study of 200
patients colonized with MDR AB, admitted to the medi-
cal ICUs of Severance Hospital, Seoul, South Korea (a
university, tertiary, referral hospital with two 15-bed
medical ICUs) from January 2008 to December 2009.
The outbreak of MDR AB infection has been developed
in the ICUs since 2008. The finger print polymerase
chain reactions for the isolated AB from the patients’
blood and from the environment were randomly per-
formed and the concordance in the types was observed.
During the study period, a total of 903 patients were
admitted to the ICUs. Screening cultures were per-
formed in blood, urine, and sputum/endotracheal aspi-
rate for all the patients at the time of ICU admission.
During the ICU stay, additional cultures were performed
every 4 to 5 days and when infection signs such as sys-
temic inflammatory response syndrome were newly
developed, or sustained for more than 3 days after anti-
biotics change, or when clinical deterioration such as
worsening of fever, respiratory condition, and/or radio-
graphic status, requiring mechanical ventilation, requir-
ing aggressive fluid resuscitation or vasopressors were
observed.
Of 903 patients, 208 (23.0%) were discharged within
48 h of ICU admission, 22 (2.4%) had been previously
colonized by MDR AB before ICU admission, 257
(28.5%) had never been colonized by MDR AB, and
416 (46.0%) were isolated with MDR AB after ICU
admission. Of these 416 patients, 216 (23.8%) were
excluded because they showed the possibility of infec-
tion with MDR AB, according to the surveillance defi-
nition of the Centers for Disease Control and
Prevention/National Healthcare Safety Network [15].
Twenty-three patients developed AB bacteremia with-
out prior colonization and 6 patients developed non-
MDR AB bacteremia. After excluding these patients,
the study population consisted of the remaining 200
patients colonized with MDR AB (Figure 1). All of the
colonization was diagnosed by endotracheal aspirate
culture and colonization of 18 patients by urine culture
at the same time.
Study Design
Baseline characteristics and various risk factors were
compared between bacteremic and non-bacteremic
patients. The risk factors were as follows: underlying ill-
ness, primary ICU admission diagnosis, acquisition types
of infection, Acute Physiological Assessment and
Chronic Health Evaluation (APACHE II) score, duration
of hospitalization, recent invasive procedures, presence
of invasive devices, prior antimicrobial therapy, immu-
nosuppression, and bacteremia due to other pathogens
before and after colonization by MDR AB. This study
protocol was approved by the Ethical Review Committee
of Severance Hospital.
Definitions
Colonization was defined as the presence of microor-
ganisms on skin, on mucous membranes, in open
wounds, or in excretions or secretions but are not caus-
ing adverse clinical signs or symptoms according to
the surveillance definition of the Centers for Disease
Control and Prevention/National Healthcare Safety
Network [15].
Nosocomial ICU-acquired bacteremia was defined on
the basis of the isolation of one or more microorgan-
isms from blood cultures 48 h after admission to the
ICU with systemic inflammatory response syndrome
(SIRS) [16]. SIRS was defined as the presence of
microbes or their toxins in the blood, or two or more of
the following conditions: (1) body temperature > 38°C
or < 36°C; (2) leukocytosis (> 10,000/mm3), leucopenia
(< 4,000/mm3), or > 10% bands; (3) heart rate > 90
beats/min; or (4) respiratory rate > 24 breaths/min [17].
Only the first isolation was considered.
The duration of exposure to risk was defined as the
time from colonization to the date a positive-culture
was obtained for MDR AB for bacteremic patients, or
the date of discharge from the ICU for non-bacteremic
patients.
The microorganism was defined as MDR if it was not
susceptible to more than three of the following eight
antimicrobial agents: ampicillin/sulbactam, aztreonam,
ceftazidime, ciprofloxacin, gentamicin, imipenem, piper-
acillin, and trimethoprim/sulfamethoxazole [18,19].
Antibiotic sensitivity was determined using the disc
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diffusion method, according to the Clinical and Labora-
tory Standards Institute guidelines [20].
The significant coagulase-negative Staphylococcus
(CNS) bacteremia was defined as isolation of the micro-
organism from 2 different blood cultures and showing
clinical signs of infection at the same time.
Immunosupression was defined as a history of any of
the following: corticosteroid therapy for 15 days (at least
10 mg/day of prednisone or an equivalent drug), sero-
positivity for human immunodeficiency virus, solid organ
transplantation, bone marrow transplantation, radiation
therapy or chemotherapy for an underlying malignancy
during the 6 months prior to hospital admission, and
acquired immune deficiency disorder (hypogammaglobu-
linemia, combined variable immunodeficiency).
Neutropenia was defined as absolute neutrophil count
< 1,500 cells/μℓ blood.
Prior utilization of healthcare services included ICU
admission or hospitalization within 90 days of the pre-
sent ICU admission.
Recent invasive procedure was defined as the use of
an invasive procedure (arterial catheter, central venous
catheter, abdominal drainage catheter, thoracic drainage
catheter/tube, nasogastric tube, urinary catheter, contin-
uous renal replacement therapy (CRRT), peritoneal dia-
lysis, tracheostomy, and endotracheal tube) within the
48 h preceding the date of the positive culture for MDR
AB for bacteremic patients, or the date of discharge
from the ICU for non-bacteremic patients.
The presence of an invasive device was defined as hav-
ing a device related to the invasive procedure for at least
48 h within the 2 weeks preceding the date of the posi-
tive culture for MDR AB for bacteremic patients, or the
date of discharge from the ICU for non-bacteremic
patients.
Prior antimicrobial therapy was defined as the use of a
systemic antimicrobial agent for at least 72 h within the
2 weeks preceding the date of the positive-culture for
MDR AB for bacteremic patients, or the date of dis-
charge from the ICU for non-bacteremic patients.
Statistical analyses
Distribution of continuous variables was tested, and that
normally and non-normally distributed variables are pre-
sented as mean ± standard deviation and median (inter-
quartile range), respectively. Categorical variables were
analyzed using the c2 test or Fisher’s exact test, and
continuous variables were analyzed using Student’s t-
test or Mann-Whitney U test. Multivariate analysis was
performed using a logistic regression model with inter-
action impacts to estimate the risk factors of occurrence
of MDR AB bacteremia and is presented with an odds
ratio (95% confidence intervals, CI). Potential candidate
variables were those with P < 0.05 in univariate analyses.
All tests were two-sided, and a p-value < 0.05 was
deemed to indicate statistical significance. SPSS 12.0
(SPSS, Chicago, IL, USA) was used for all statistical
analyses.
Figure 1 Summary of the study design. ICU intensive care unit. MDR multi-drug resistant. AB Acinetobacter baumannii.
Jung et al. BMC Infectious Diseases 2010, 10:228
http://www.biomedcentral.com/1471-2334/10/228
Page 3 of 11
Results
Patient characteristics
Baseline characteristics of the study population are
shown in Table 1. Of the 200 patients colonized with
MDR AB, 108 (54.0%) developed MDR AB bacteremia,
and 92 (46.0%) did not. Among 108 episodes of MDR
AB bacteremia, carbapenem sensitive AB was observed
in 15 (13.9%) patients. There was no difference between
the two groups in terms of age or gender. Significantly
more patients with bacteremia had malignancies and
organ/bone marrow transplants as underlying illnesses,
and significantly more patients without bacteremia had
central nervous system disorders. The most common
reason for ICU admission in both groups was infection.
Infection (94.4% vs. 71.7%; P < 0.001) and respiratory
failure (39.8% vs. 8.7%; P < 0.001) were more frequently
observed in bacteremic than in non-bacteremic patients.
Infection in 56.1% of non-bacteremic patients was com-
munity-acquired, and in 45.1% of bacteremic patients
was hospital-acquired (P = 0.037).
Risk factors related to clinical characteristics
Table 2 shows the univariate analysis of risk factors
related to clinical characteristics. Immunosupression,
neutropenia, and APACHE II score at ICU admission
were significant risk factors. APACHE II score, shock,
Table 1 Demographic Data of Non-Bacteremic and Bacteremic Patientsa
Parameters Non-Bacteremic
(n = 92)
Bacteremic
(n = 108)
P-value
Age (yrs) 61.9 ± 15.6 61.6 ± 15.4 0.865
Gender
Men
Women
55 (59.8)
64 (59.3)
37 (40.2)
44 (40.7)
0.940
Underlying illness
Diabetes mellitus 29 (31.5) 32 (29.6) 0.772
Lung disease 19 (20.7) 12 (11.1) 0.063
Central nervous system disorders 28 (30.4) 13 (12.0) 0.001
Renal disease 10 (10.9) 12 (11.1) 0.957
Hypertension 36 (39.1) 39 (36.1) 0.660
Cardiovascular disease 16 (17.4) 13 (12.0) 0.284
Liver disease 5 (6.5) 15 (13.9) 0.09
Rheumatologic disease 0 (0) 4 (3.7) 0.062
Malignancy 18 (19.6) 64 (59.3) < 0.001
Solid organ malignancy 14 (15.2) 33 (30.6) 0.011
Hematologic malignancy 5 (5.4) 31 (28.7) < 0.001
HIV infection 0 (0) 2 (1.9) 0.190
Organ or Bone Marrow Transplantation 1 (1.1) 12 (11.1) < 0.001
Primary ICU admission diagnosis
Infection 66 (71.7) 102 (94.4) < 0.001
Respiratory failure 8 (8.7) 43 (39.8) < 0.001
Pulmonary bleeding 2 (2.2) 1 (0.9) 0.595
Gastrointestinal bleeding 3 (3.3) 3 (2.8) 1.000
Liver failure 8 (8.7) 3 (2.8) 0.067
Cardiologic disease 3 (3.3) 2 (1.9) 0.663
Endocrinologic disease 1 (1.1) 0 (0) 0.460
Other 8 (8.7) b 9 (8.3) c 0.927
Acquisition of Infection d
Community-acquired 37 (56.1) 37 (36.3) 0.037
Hospital-acquired 19 (28.8) 46 (45.1)
Healthcare-associated 10 (15.1) 19 (18.6)
a Data are presented as numbers (percentages) unless otherwise indicated. Plus-minus values are means ± standard deviation
b Mental change (6), post-operative care (2)
c Renal failure (3), brain hemorrhage (2), mental change (2), post-operative care (2)
d Number of patients/total number of patients who were admitted to ICU due to infection (percentages)
HIV human immunodeficiency virus
ICU intensive care unit
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and acute renal failure at the time of colonization were
significantly correlated with the development of MDR
AB bacteremia. After colonization, it took about 6 days
to develop bacteremia. The duration of time at risk was
longer in non-bacteremic patients than in bacteremic
patients (12.1 ± 19.3 vs. 6.0 ± 11.1 days; P = 0.016). The
intubation rate was not different between the groups,
but maintenance of mechanical ventilation was a signifi-
cant risk factor, with an odds ratio of 31.2 (95% CI
14.14-68.83; P < 0.001). Furthermore, the longer the
mechanical ventilation was maintained, the further the
progression of bacteremia (odds ratio = 1.04; 95% CI
1.01-1.08; P = 0.018). It took about 7 days to be colo-
nized with MDR AB from the time of ICU admission in
both groups.
Risk factors related to recent invasive procedures and
presence of invasive devices
Table 3 shows the univariate analysis of risk factors related
to recent invasive procedures and the presence of invasive
devices. Receipt of any one of the invasive procedures
within 48 h of the date of a positive-culture for bacteremic
patients or the date of discharge from the ICU for non-
bacteremic patients, was a significant risk factor for MDR
AB bacteremia (odds ratio = 3.85; 95% CI 1.45-10.24; P =
0.007). Patients in whom either an arterial catheter or a
central venous catheter was inserted, or patients who
received CRRT were at risk of MDR AB bacteremia.
Among the inserted invasive devices, central venous cathe-
ter, CRRT catheter, and thoracic drainage catheter/tube
were significant risk factors. Patients in whom an
Table 2 Risk factors related to clinical characteristicsa
Parameters Non-Bacteremic
(n = 92)
Bacteremic
(n = 108)
Odds
Ratio
95% CI P-value
Immunosuppressive status b 45 (48.9) 89 (82.4) 4.89 2.57 - 9.29 < 0.001
Neutropenia c 2 (2.2) 25 (23.1) 13.55 3.11 - 59.0 0.001
Prior history of
ICU admission 2 (2.2) 6 (5.6) 2.65 0.52 - 13.45 0.240
Hospitalization 24 (26.1) 41 (38.0) 1.73 0.95 - 3.18 0.075
APACHE II score at the time of
ICU admission (point) 21.6 ± 8.2 24.0 ± 7.9 1.04 1.00 - 1.08 0.035
Colonization (point) 17.0 (12.0 - 20.0) 22.0 (17.0 - 28.0) 1.12 1.07 - 1.17 <0.001
Duration (days)
Of hospitalization 31.0 (20.0 - 65.3) 32.0 (20.0 - 5.0) 0.99 0.99 - 1.00 0.333
Of ICU hospitalization 19.2 ± 21.3 22.8 ± 20.4 1.01 0.99 - 1.02 0.234
From ICU admission to colonization 7.1 ± 7.7 7.2 ± 5.9 1.00 0.96 - 1.01 0.923
Of exposure to riskd 6.0 (3.0 - 13.8) 3.0 (1.0 - 6.0) 0.96 0.94 - 0.99 <0.001
Mechanical ventilator care 87 (94.6) 105 (97.2) 2.01 0.47 - 8.66 0.348
Maintenance of MVe 15 (17.2) 91 (86.7) 31.2 14.14 - 68.83 < 0.001
Duration of MV (day) 9.0 (5.0 - 16.0) 21.5 (12.3 - 47.0) 1.04 1.01 - 1.08 0.001
Shock at the time of
ICU admission 66 (71.7) 80 (74.1) 1.13 0.60 - 2.10 0.711
Colonization 28 (30.4) 65 (60.2) 3.46 1.92 - 6.22 < 0.001
Acute renal failure at the time of
ICU admission 22 (23.9) 31 (28.7) 1.28 0.68 - 2.42 0.445
Colonization 20 (21.7) 41 (38.0) 2.20 1.17 - 4.14 0.014
a Data are presented as numbers (percentages for categorical variables or interquartile range for continuous variables) unless otherwise indicated. Plus-minus
values are means ± standard deviation
b Immunosupression was defined as a history of any of the following: corticosteroid therapy for 15 days (at least 10 mg/day of prednisone or an equivalent
drug), seropositivity for human immunodeficiency virus, solid organ transplantation, bone marrow transplantation, radiation therapy or chemotherapy for an
underlying malignancy during the 6 months prior to hospital admission, and acquired immune deficiency disorder (hypogammaglobulinemia, combined variable
immunodeficiency).
c Neutropenia is defined as absolute neutrophil count measured in cells per microliter of blood less than 1,500
d Time from colonization to the date of discharge from the intensive care unit for non-bacteremic patients or to the date a positive-culture was obtained for
bacteremic patients
e Number of patients/total number of patients with mechanical ventilation (percentages)
ICU intensive care unit
APACHE Acute Physiological Assessment and Chronic Health Evaluation
MV mechanical ventilation
CI confidential interval
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endotracheal tube was maintained developed MDR AB
bacteremia significantly more than those who were
switched to a tracheostomy tube.
Risk factors related to bacteremia with other
microorganisms
Table 4 shows risk factors related to bacteremia caused
by other microorganisms before and after colonization
by MDR AB. Bacteremia developing in both periods was
a significant risk factor for MDR AB bacteremia, with
odds ratios of 2.59 (95% CI 1.35-4.99; P = 0.004) and
3.06 (95% CI 1.48-6.36; P = 0.004), respectively. Before
colonization by MDR AB, bacteremia caused by other
microorganisms was observed in 37.0% of bacteremic
and 18.5% of non-bacteremic patients. CNS (38.0%) was
the most common pathogen in bacteremic patients, and
fungus (23.5%) in non-bacteremic patients. During the
period of time at risk after colonization, bacteremia was
observed in 31.5% of bacteremic and 13.0% of non-bac-
teremic patients. Enterococcus species (51.5%) were most
commonly isolated from bacteremic patients and CNS
(33.3%) from non-bacteremic patients.
Risk factors related to prior antimicrobial therapy
Table 5 shows risk factors related to prior antimicrobial
therapy. The average number of prior antimicrobials
used was 3.8 in bacteremic patients and 2.7 in non-bac-
teremic patients (P < 0.001). Quinolones, carbapenems,
glycopeptides, and aminoglycosides were more fre-
quently used in bacteremic than in non-bacteremic
patients.
Multivariate analysis of risk factors for multi-drug
resistant Acinetobacter baumannii bacteremia
Table 6 shows the results of the multivariate analysis of
risk factors for MDR AB bacteremia. Five independent
Table 3 Risk factors related to recent invasive procedures and presence of invasive devicesa
Parameters Non-Bacteremic
(n = 92)
Bacteremic
(n = 108)
Odds
Ratio
95% CI P-value
Recent invasive procedureb 75 (81.5) 102 (94.4) 3.85 1.45 - 10.24 0.007
Arterial catheter 4 (4.3) 15 (13.9) 3.55 1.13 - 11.10 0.030
Central venous catheter 6 (6.5) 29 (26.9) 5.26 2.08 - 13.34 < 0.001
Abdominal drainages 1 (1.1) 5 (4.6) - - -
Thoracic drainage 0 (0) 2 (1.9) - - -
Nasogastric tube 18 (19.6) 11 (10.2) 0.47 0.21 - 1.05 0.064
Urinary catheter 11 (12.0) 17 (15.7) 1.38 0.61 - 3.11 0.443
CRRT 4 (4.3) 27 (25.0) 7.33 2.46 - 21.9 < 0.001
Peritoneal dialysis 2 (2.2) 0 (0) - - -
Tracheostomy 1 (1.1) 3 (2.8) - - -
Other procedures 3 (3.3) c 7 (6.3) d 1.39 0.44 - 4.41 0.574
Presence of invasive devicee 92 (100) 108 (100) - - -
Arterial catheter 84 (91.3) 96 (88.9) 0.76 0.29 - 1.95 0.571
Central venous catheter 82 (89.1) 107 (99.1) 13.05 1.64 - 103.99 0.015
Abdominal drainages 3 (3.3) 5 (4.6) 1.44 0.34 - 6.19 0.624
Thoracic drainage 4 (4.3) 18 (16.7) 4.40 1.43 - 13.52 0.006
Nasogastric tube 90 (97.8) 106 (98.1) 1.18 0.16 - 8.53 0.871
Urinary catheter 91 (98.9) 105 (97.2) 0.39 0.04 - 3.76 0.412
CRRT 7 (7.6) 36 (33.3) 6.07 2.55 - 14.47 < 0.001
Peritoneal dialysis 2 (2.2) 1 (0.9) 0.42 0.04 - 4.71 0.482
Endotracheal tube 46 (55.4) 80 (76.9) 2.72 1.47 - 5.04 0.001
Other devices 2 (2.2)f 1 (0.9)g 0.42 0.04 - 4.71 0.482
a Data are presented as numbers (percentages) unless otherwise indicated
b Use of an invasive procedure within the 48 h preceding the date of the positive culture for MDR AB for bacteremic patients, or the date of discharge from the
ICU for non-bacteremic patients
c Pericardial drainage catheter insertion (1), buttock abscess drainage catheter insertion (1), fiberoptic bronchoscopy (1)
d Fiberoptic bronchoscopy (3), esophagogastroduodenoscopy (1), extracorporeal membrane oxygenation catheter insertion (1), spinal tapping (1), tracheoscopy
(1)
e Having a device related to the invasive procedure for at least 48 h within the 2 weeks preceding the date of the positive culture for MDR AB for bacteremic
patients, or the date of discharge from the ICU for non-bacteremic patients
f Pericardial drainage catheter (1), buttock abscess drainage catheter (1)
g Extracorporeal membrane oxygenation catheter (1)
CRRT continuous renal replacement therapy
CI confidential interval
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risk factors associated with MDR AB bacteremia were
identified: ICU admission due to infection (odds ratio =
12.04; 95% CI 1.79-80.74; P = 0.01), ICU admission due
to respiratory failure (odds ratio = 9.35; 95% CI 2.16-
40.45; P = 0.003), recent central venous catheter inser-
tion (odds ratio = 10.40; 95% CI 1.98-54.75; P = 0.006),
bacteremia caused by other microorganisms after MDR
AB colonization (odds ratio = 4.89; 95% CI 1.37-17.47;
P = 0.014), and number of prior antimicrobials used
(odds ratio = 2.12; 95% CI 1.33-3.39; P = 0.002). The
interaction was observed only between the variables of
maintenance of mechanical ventilation and maintenance
of an endotracheal tube instead of switching to tra-
cheostomy, but combined two factors was a significant
Table 4 Risk factors related to bacteremia with other microorganismsa
Parameters Non-Bacteremic
(n = 92)
Bacteremic
(n = 108)
Odds
Ratio
95% CI P-value
Prior other bacteremia before colonization 17 (18.5) 40 (37.0) 2.59 1.35 - 4.99 0.004
MRSA 1 (5.9) 2 (5.1) 1.72 0.15 - 19.25 0.661
MSSA 2 (11.8) 1 (2.6) 0.42 0.38 - 4.71 0.482
CNS 1 (5.9) 12 (30.8) 12.45 1.59 - 97.14 0.016
Streptococcus pneumonia 0 (0) 1 (2.6) - - -
Streptococcus other 2 (11.8) 3 (7.7) 1.29 0.21 - 7.87 0.786
Enterococcus species 2 (11.8) 9 (23.1) 4.09 0.86 - 19.44 0.076
Pseudomonas aeruginosa 1 (5.9) 2 (5.1) 1.72 0.15 - 19.25 0.661
Escherichia coli 3 (17.6) 8 (20.5) 2.37 0.61 - 9.22 0.212
Klebsiella pneumonia 0 (0) 3 (7.7) - - -
Enterobacter species 1 (5.9) 1 (2.6) 0.85 0.05 - 13.79 0.910
Stenotrophomonas maltophilia 1 (5.9) 1 (2.6) 1.28 0.59 - 2.77 0.532
Serratia marcescens 2 (11.8) 1 (2.6) 0.42 0.04 - 4.71 0.482
Other Gram-positive pathogens 0 (0) 0 (0) - - -
Other Gram-negative pathogensb 0 (0) 3 (7.7) - - -
Fungus 4 (23.5) 8 (20.5) 1.76 0.51 - 6.05 0.369
Aanerobes 0 (0) 0 (0) - - -
Polymicrobial bacteremia 1 (5.9) 3 (7.7) 2.60 0.27 - 25.43 0.412
Prior other bacteremia after colonization 12 (13.0) 34 (31.5) 3.06 1.48 - 6.36 0.003
MRSA 0 (0) 1 (3.0) - - -
MSSA 2 (16.7) 2 (6.1) 0.85 0.12 - 6.15 0.871
CNS 4 (33.3) 10 (30.3) 2.25 0.68 - 7.41 0.185
Streptococcus pneumonia 0 (0) 0 (0) - - -
Streptococcus other 0 (0) 0 (0) - - -
Enterococcus species 1 (8.3) 17 (51.5) 18.2 2.38 - 139.22 0.005
Pseudomonas aeruginosa 0 (0) 5 (12.1) - - -
Escherichia coli 0 (0) 1 (3.0) - - -
Klebsiella pneumonia 1 (8.3) 1 (3.0) 0.85 0.05 - 13.79 0.909
Enterobacter species 0 (0) 1 (3.0) - - -
Stenotrophomonas maltophilia 1 (8.3) 1 (3.0) 0.85 0.05 - 13.79 0.909
Serratia marcescens 0 (0) 1 (3.0) - - -
Other Gram-positive pathogens 0 (0) 0 (0) - - -
Other Gram-negative pathogensc 1 (8.3) 0 (0) - - -
Fungus 1 (8.3) 7 (21.2) 6.31 0.76 - 52.25 0.088
Aanerobesd 1 (8.3) 0 (0) - - -
Polymicrobial bacteremia 0 (0) 6 (17.6) - - -
a Data are presented as numbers (percentages) unless otherwise indicated
b Chryseobacterium indologenes, Morganella morganii, Citrobadter freundii
c Chryseobacterium meningosepticum
d Norcardia farcinica
MRSA methicillin-resistant Staphylococcus aureus
MSSA methicillin-sensitive Staphylococcus aureus
CNS coagulase negative Staphylococcus
CI confidential interval
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risk factor for MDR AB bacteremia (odds ratio = 16.64;
95% CI 1.64-168.83; P = 0.017).
Discussion
This was a retrospective, observational study to deter-
mine risk factors for MDR AB nosocomial bacteremia in
patients colonized with MDR AB after ICU admission.
Our study showed that the presence of infection and
respiratory failure at the time of ICU admission, recent
central venous catheter insertion, bacteremia caused by
other microorganisms after colonization by MDR AB,
and prior antimicrobial therapy, were the independent
risk factors for MDR AB bacteremia. Moreover,
combined factors of maintenance on a mechanical venti-
lator and maintenance of an endotracheal tube instead
of switching to a tracheostomy, increased the risk of
MDR AB bacteremia.
Risk factors for AB bacteremia in the ICU have pre-
viously been demonstrated with case-control and cohort
methodologies. Multivariate analysis identified male gen-
der, APACHE II score, length of stay in the ICU,
mechanical ventilation, prior infection, antimicrobial
therapy, prior colonization, and colonization pressure as
independent risk factors for AB bacteremia [4,6,7,9].
Recently, epidemic outbreaks of MDR AB have occurred
in different areas of hospitals, primarily the ICU, with
Table 5 Risk factors related to prior antimicrobial therapya
Non-
Bacteremic
(n = 92)
Bacteremic
(n = 108)
Odds
Ratio
95% CI P-
value
Non-
Bacteremic
(days)
Bacteremic
(days)
P-
value
Number (percentage) of prior exposure antibiotics/
duration of exposure, days
2.7 ± 1.1 3.8 ± 1.4 2.09 1.60 -
2.74
<
0.001
19.2 ± 21.3 13.2 ± 12.9 0.005
Aminopenicillin 2 (2.2) 3 (2.8) 1.29 0.21 -
7.87
0.79 9.5 ± 2.1 6.7 ± 6.4 0.601
Cephalosporin 34 (37.0) 34 (31.5) 0.78 0.44 -
1.41
0.416 11.2 ± 9.1 7.9 ± 6.8 0.09
Quinolone 37 (40.2) 50 (55.6) 1.86 1.06 -
3.27
0.031 11.6 ± 6.2 7.8 ± 3.4 0.002
Antipseudomonal penicillin 34 (37.0) 44 (40.7) 1.17 0.66 -
2.08
0.585 10.6 ± 5.1 6.3 ± 2.9 <
0.001
Carbapenem 45 (48.9) 83 (76.9) 3.47 1.89 -
6.36
<
0.001
14.1 ± 14.9 9.2 ± 6.0 0.003
Glycopeptide 52 (56.5) 85 (78.7) 2.84 1.53 -
5.28
0.001 12.6 ± 7.6 9.3 ± 7.8 0.018
Aminoglycoside 10 (10.9) 30 (27.8) 3.15 1.45 -
6.88
0.004 8 ± 4.1 5.6 ± 3.8 0.099
Anti-anaerobe 24 (26.1) 38 (35.2) 1.54 0.84 -
2.83
0.167 9.0 ± 4.6 6.3 ± 4.1 0.017
Macrolide 2 (2.2) 5 (4.6) 2.18 0.41 -
11.54
0.357 5.5 ± 3.5 4.4 ± 2.6 0.660
a Data are presented as numbers (percentages) unless otherwise indicated. Plus-minus values are means ± standard deviation
CI confidential interval
SD standard deviation
Table 6 Multivariate analysis of risk factors for multi-drug resistant Acinetobacter baumannii bacteremia
Risk Factors Odds ratio 95% CI P-value
Reason for ICU admission
Infection 12.04 1.79 - 80.74 0.010
Respiratory failure 9.35 2.16 - 40.45 0.003
Maintenance of mechanical venitlation 10.36 2.06 - 52.25 0.005
Maintenance of endotracheal tube 2.19 0.45 - 10.57 0.331
Recent centeral venous catheter insertion 10.40 1.98 - 54.75 0.006
Bacteremia of other microorganisms after colonization 4.89 1.37 - 17.47 0.014
Number of prior antibiotics used 2.12 1.33 - 3.39 0.002
Maintenance of mechanical ventilation × maintenance of endotracheal tube a 16.64 1.64 - 168.83 0.017
a Interaction impacts of maintenance of mechanical ventilation and maintenance of endotracheal tube instead of a switch to tracheostomy
ICU intensive care unit
CI confidential interval
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widespread dissemination and colonization [10,19].
However, knowledge of which patients previously colo-
nized with MDR AB would develop bacteremia in the
ICU has been limited. Awareness of the risk factors
would help predict bacteremia in colonized patients and
allow administration of appropriate antibiotics before
culture results are reported. Delay in appropriate antimi-
crobial therapy has an adverse influence on the clinical
outcome of patients with AB bacteremia [12,13,18].
Consistent with other studies [3,4], we found the pre-
sence of infection at the time of ICU admission, and
bacteremia caused by other microorganisms after MDR
AB colonization, independently increased the risk of
MDR AB bacteremia 12-and 5-fold, respectively. Infec-
tion accompanied by bacteremia caused by other micro-
organisms reflects underlying disease severity or a
requirement for critical care, including invasive inter-
ventions. These risk factors are also related to the num-
ber of previous antimicrobials used which increased the
risk of MDR AB bacteremia by 2-fold in the present
study. Treatment with a greater number of broad-spec-
trum antibiotics is a surrogate marker of illness severity,
and could ablate a patient’s pre-existing microflora.
Duration of exposure to previous antimicrobials was sig-
nificantly shorter in bacteremic than in non-bacteremic
patients, but this result was due to shorter duration
of risk exposure. Therefore, the number of previous
antimicrobials used at least 72 h within 2 weeks were
analyzed in this study.
Our data showed combined factors of maintenance of
mechanical ventilation and maintenance of an endotra-
cheal intubation tube without a switch to tracheostomy,
increased the risk of bacteremia by almost 17-fold.
Mechanical ventilation is the main source of transmis-
sion of AB, and AB colonization in the respiratory
tract. Tracheobronchitis and pneumonia are known to
increase the risk of secondary bacteremia caused by AB
in other studies [4-6, 21-23]. In a univariate analysis of
risk factors, it was reported that tracheostomy was a sig-
nificant risk factor for AB colonization [8]. In the pre-
sent study, it was not identified as a significant risk
factor, because only a small number of recent tracheo-
stomies was included.
Recent central venous catheter insertion increased the
risk of bacteremia by almost 10-fold. Central venous
catheter insertion has previously been reported as a risk
factor for AB bacteremia on the basis of univariate ana-
lyses [2,6,24]. In this study, using multivariate analysis, it
was a significant independent risk factor. The difference
is a result of the different types of patients included in
the study populations; previous studies compared
patients with and without infection of MDR AB. All
patients in this study were colonized by MDR AB; thus,
the risk of development of bacteremia due to invasive
procedures was significant. As with many other invasive
procedures, central venous catheter insertion is a major
portal of entry as a source of infection [6]. Arterial
catheter insertion was a significant risk factor on the
basis of a univariate, but not a multivariate, analysis.
Although both procedures are performed via a vascular
access, the sizes of the puncture needle and guide
sheath/wire differ. The chances of developing blood
stream infections depend on the length of the devices
used and the duration of the procedures.
Previous reports were unclear as to whether a longer
stay in the ICU would increase the risk for bacteremia
[3,7,8,25-27]. Many other possible risk factors for noso-
comial MDR AB bacteremia in the ICU are related to
length of hospitalization. To control for the duration of
time at risk, we included the time from colonization to
the date of a positive-culture for MDR AB for bactere-
mic patients or to the date of discharge from the ICU
for non-bacteremic patients in the final multivariate
analysis. The results showed that the duration of expo-
sure to risk was not an independently significant risk
factor; in fact, univariate analysis showed it was actually
shorter in bacteremic than in non-bacteremic patients.
As all the patients in this study were already colonized
with MDR AB, the length of stay in the ICU did not
affect the development of MDR AB bacteremia; even
with a short duration of stay, patients requiring acute
care and those maintaining mechanical ventilation and
receiving invasive procedures developed bacteremia
more frequently.
AB infection or colonization is associated with
increased mortality, morbidity, and a prolonged length
of stay in the hospital, leading to excessive medical costs
[19,25]. Reducing intrinsic contamination and colo-
nization of medical equipment or devices used for
monitoring and therapy of patients, and decreasing con-
tamination through airborne or direct contact with
patients must be the primary measure used to control
the infection of MDR AB in the ICU. Furthermore,
attention to various guidelines for the use of care bun-
dles in critical care, such as ventilator bundles, central
line bundles, and severe sepsis bundles is important for
the prevention of bacteremia in clinical practice, espe-
cially for patients colonized with MDR AB. Moreover,
efforts to remove invasive devices and equipment such
as endotracheal tube or central venous catheter as soon
as possible are needed to prevent development of MDR
AB bacteremia among the colonized patients [2,12,13].
There are several limitations to the present study.
First, this study was processed in a retrospective obser-
vational manner; thus, methodological deficiencies in
assessing risk factors for MDR AB acquisition may lead
to biased estimates or erroneous associations. However,
number of patients in this study is larger than previous
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studies [3,6,21], so potential for bias is expected to be
minimized. Second, since active surveillance culture for
the presence of AB was not routinely and uniformly
performed during ICU stay, not all the patients with
colonization may have been included in this study and
there may be inaccuracy in the timing of colonization.
Third, because outbreak of MDR AB was developed
during the study period, this result may not represent
overall status of MDR AB bacteremia of the patients
with prior colonization in general ward or other inten-
sive care units. Lastly, although we followed the defini-
tion of the Centers for Disease Control and Prevention/
National Healthcare Safety Network to select the
patients colonized by MDR AB, some of the patients
included in this study might have been infected with
MDR AB, while some of those that were excluded
might have been colonized by MDR AB.
Conclusions
In conclusion, this study demonstrated the several risk
factors for MDR AB nosocomial bacteremia in patients
with MDR AB colonization in the ICU. Independent
risk factors were the presence of infection and respira-
tory failure at the time of ICU admission, maintenance
of mechanical ventilation, maintenance of an endotra-
cheal tube instead of a switch to a tracheostomy, recent
central venous catheter insertion, bacteremia caused by
other microorganism after colonization with MDR AB,
and prior antimicrobial therapy. Patients in the ICU,
colonized with MDR AB, should be considered for mini-
mizing invasive procedures and early removal of the
invasive devices or equipments to prevent development
of bacteremia [2].
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